MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s40635-025-00777-1

Медицинская библиотека · Intensive care medicine experimental · 2025

29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.

Kyriazopoulou Evdoxia, Kotsaki Antigone, Safarika Asimina, Poulakou Garyfallia, Milionis Haralampos, Metallidis Simeon, Adamis Georgios, Fragkou Archontoula, Rapti Aggeliki, Del Vecchio Pierluigi, Kalomenidis Ioannis, Kitzoglou Danae, Angheben Andrea, Kainis Ilias, Iliopoulou Konstantina, Serino Francesco Saverio, Bakakos Petros, Tzavara Vassiliki, Ioannou Sofia, Dagna Lorenzo, Dimakou Katerina, Tzatzagou Glykeria, Chini Maria, Bassetti Matteo, Kotsis Vasileios, Tsoukalas George, Selmi Carlo, Nikolakopoulou Sofia, Samarkos Michael, Doumas Michael, Masgala Aikaterini, Papanikolaou Ilias, Argyraki Aikaterini, Akinosoglou Karolina, Symbardi Styliani, Panagopoulos Periklis, Dalekos George N, Liesenfeld Oliver, Sweeney Timothy E, Khatri Purvesh, Giamarellos-Bourboulis Evangelos J

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Biomarkers based on host response signatures are currently under development for the critically ill. We applied a 29-mRNA classifier for the diagnosis and prognosis of suspected acute infection and sepsis (TriVerity™, Inflammatix Inc.) in patients hospitalized with COVID-19.

METHODS

We applied three scores from locked classifiers (IMX-BVN-4 and IMX-SEV-4) from the 29-mRNA TriVerity™ blood test in participants of the SAVE-MORE randomized clinical trial (ClinicalTrials.gov NCT04680949) at baseline and days 4 and 7 of treatment, to classify bacterial infection, viral infection and decompensation. Participants were adults hospitalized with confirmed COVID-19 pneumonia and plasma soluble urokinase plasminogen activator receptor (suPAR) levels of ≥ 6 ng/ml, randomized to placebo or anakinra treatment.

RESULTS

A total of 471 patients were studied. At baseline nearly 90% had a Very Low or Low IMX-BVN-4 Bacterial Score and Moderate, High or Very High IMX-BVN-4 Viral Score. Anakinra treatment had an effect on the expression of genes indicating IMX-SEV-4 High or Very High scores after a 7 day treatment compared to baseline (12.9% of anakinra-treated patients continued being classified as high severity vs 20.4% of placebo-treated patients, p 0.046).

CONCLUSIONS

The classifiers were well tested in COVID-19 pneumonia and may become a useful tool for hospitalized patients.

Для цитирования: Kyriazopoulou Evdoxia, Kotsaki Antigone, Safarika Asimina, Poulakou Garyfallia, Milionis Haralampos, Metallidis Simeon, Adamis Georgios, Fragkou Archontoula, Rapti Aggeliki, Del Vecchio Pierluigi, Kalomenidis Ioannis, Kitzoglou Danae, Angheben Andrea, Kainis Ilias, Iliopoulou Konstantina, Serino Francesco Saverio, Bakakos Petros, Tzavara Vassiliki, Ioannou Sofia, Dagna Lorenzo, Dimakou Katerina, Tzatzagou Glykeria, Chini Maria, Bassetti Matteo, Kotsis Vasileios, Tsoukalas George, Selmi Carlo, Nikolakopoulou Sofia, Samarkos Michael, Doumas Michael, Masgala Aikaterini, Papanikolaou Ilias, Argyraki Aikaterini, Akinosoglou Karolina, Symbardi Styliani, Panagopoulos Periklis, Dalekos George N, Liesenfeld Oliver, Sweeney Timothy E, Khatri Purvesh, Giamarellos-Bourboulis Evangelos J. 29-mRNA host response signatures for classification of bacterial infection, viral infection and disease progression in COVID-19 pneumonia: a post hoc analysis of the SAVE-MORE randomized clinical trial.. Intensive care medicine experimental. 2025. DOI: 10.1186/s40635-025-00777-1.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.